Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials.

CONCLUSION: The therapeutic benefit of additional substances is less distinct in patients with RAS mutated as compared to RAS wildtype metastatic colorectal cancer, especially with regard to OS. PMID: 32561975 [PubMed - indexed for MEDLINE]

https://www.ncbi.nlm.nih.gov/pubmed/32561975?dopt=Abstract

Source: Clin Med Res - July 15, 2020 Category: Research Authors: Stahler A, Heinemann V, Ricard I, von Einem JC, Giessen-Jung C, Westphalen CB, Michl M, Heinrich K, Miller-Phillips L, Jelas I, Stintzing S, Modest DP Tags: J Cancer Res Clin Oncol Source Type: research